Platelet adhesion receptors: Novel targets for anti-thrombotic therapy

Australian and New Zealand Journal of Medicine

Volumn 29, Issue 3, 1999, Pages 452-461

  Williamson, D ^a   Giuliano, S ^a   Jackson, S P ^b  

^a MONASH UNIVERSITY   (Australia)

^b MONASH UNIVERSITY MEDICAL SCHOOL   (Australia)

Author keywords

Adhesion receptors; Antithrombotic agents; GP IIb IIIa inhibitors; Platelets; Thrombosis

Indexed keywords

3 [[3 [4 (AMINOIMINOMETHYL)PHENYL] 4,5 DIHYDRO 5 ISOXAZOLYL]ACETAMIDO] N [(3,5 DIMETHYL 4 ISOXAZOLYL)SULFONYL]ALANINE; 3 [[4 [4 [AMINO(ETHOXYCARBONYLIMINO)METHYL]PHENYL] 2 THIAZOLYL](1 ETHOXYCARBONYLMETHYL 4 PIPERIDINYL)AMINO]PROPIONIC ACID ETHYL ESTER; 3 [[4 [[4 (AMINOIMINOMETHYL)PHENYL]AMINO] 1,4 DIOXOBUTYL]AMINO] 4 PENTYNOIC ACID; 4 (4 AMIDINOBENZOYLGLYCYL) 3 METHOXYCARBONYLMETHYL 2 OXO 1 PIPERAZINEACETIC ACID; 4 [4 [4 (AMINOIMINOMETHYL)PHENYL] 1 PIPERAZINYL] 1 PIPERIDINEACETIC ACID; ABCIXIMAB; ACETYLCYSTEINYLASPARAGINYL 5,5 DIMETHYLTHIOPROLYL 4 AMINOMETHYLPHENYLALANYLGLYCYLASPARTYLCYSTEINE; ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; FRADAFIBAN; LAMIFIBAN; LEFRADAFIBAN; N ACETYLCYSTEINYLASPARAGINYLPROLYLARGINYLGLYCYLASPARTYL(O METHYLTYROSYL)ARGINYLCYSTEINAMIDE CYCLIC 1,9 DISULFIDE; N ETHYL N [4 (4 PIPERIDINYL)BUTYRYL]GLYCYLASPARTYL 3 CYCLOHEXYLALANINAMIDE; ORBOFIBAN; SIBRAFIBAN; SKB 214857; TICLOPIDINE; TIROFIBAN; UNCLASSIFIED DRUG; XEMILOFIBAN; YM 35337;

CONFERENCE PAPER; CORONARY ARTERY THROMBOSIS; DRUG EFFICACY; DRUG MECHANISM; HEART MUSCLE ISCHEMIA; HUMAN; THROMBOCYTE ADHESION; THROMBOCYTE AGGREGATION; THROMBOCYTE AGGREGATION INHIBITION;

EID: 0033025976     PISSN: 00048291     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1445-5994.1999.tb00742.x     Document Type: Conference Paper

References (61)

1. 1. Chapman I. Morphogenesis of occluding coronary artery thrombosis. Arch Pathol 1965; 80: 256-61.
2. 2. Friedman M, Van den Bovenkamp GJ. The pathogenesis of coronary thrombosis. Am J Pathol 1996; 48: 19-44.
3. 3. Fuster V, Badimon L, Badimon JJ, Chesebro J. The pathogenesis of coronary artery disease and the acute coronary syndromes. N Engl J Med 1992; 326: 310-18.
4. 4. Schafer AI, Kroll MH. Nonatheromatous arterial thrombosis. Ann Rev Med 1993; 44: 155-70.
5. 5. Sakariassan KS, Bolhuis PA, Sixma JJ. Human blood platelet adhesion to artery subendothelium is mediated by factor VIII/von Willebrand factor bound to the subendothelium. Nature 1979; 279: 636-8.
6. 6. Savage B, Saldivav E, Ruggeri ZM. Initiation of platelet adhesion by arrest onto fibrinogen or translocation on von Willebrand factor. Cell 1996; 84: 289-97.
7. 7. Crockett-Torabi E. Selectins and mechanisms of signal transduction. J Leukoc Biol 1998; 63: 1-14.
8. 8. Rossiter H, Alon R, Kupper TS. Selectins, T-cell rolling and inflammation. Mol Med Today 1997; 3: 214-22.
9. 9. Kroll MH, Harris TS, Moake JL, Handin RI, Schafer AI. von Willebrand factor binding to platelet GP Ib initiates signals for platelet activation. J Clin Invest 1991; 88: 1568-73.
10. 10. Chow TW, Hellums JD, Moake JL, Kroll MH. Shear stress induced von Willebrand factor binding to platelet glycoprotein Ib initiates calcium influx associated with aggregation. Blood 1992; 80: 113-20.
11. 11. Ikeda Y, Handa M, Kanata T et al. Transmembrane calcium influx associated with von Willebrand factor binding to GP Ib in the initiation of shear-induced platelet aggregation. Thromb Haemost 1993; 69: 496-502.
12. 12. Zahger D, Fishbein MC, Garfinkel LI et al. VCL, an antagonist of the platelet GPIb receptor, markedly inhibits platelet adhesion and intimai thickening after balloon injury in the rat. Circulation 1995; 92: 1269-73.
13. 13. Yao S-K, Ober JC, Garfinkel LI et al. Blockade of platelet membrane glycoprotein Ib receptors delays intracoronary thrombogenesis, enhances thrombolysis, and delays coronary artery reocclusion in dogs. Circulation 1994; 89: 2822-8.
14. 14. Tcheng JE. Glycoprotein IIb/IIIa receptor inhibitors: putting the EPIC, IMPACT II, RESTORE and EPILOG trials into perspective. Am J Cardiol 1996; (Suppl. 3A) 78: 34-40.
15. 15. Lopez JA, Andrews RK, Afshar-Kharghan V, Berndt MC. Bernard-Soulier syndrome. Blood 1998; 91: 4397-418.
16. 16. Lopez JA, Chung DW, Fujikawa K et al. The α and ß chains of human platelet glycoprotein Ib are both trans-membrane proteins containing a leucine-rich amino acid sequence. Proc Natl Acad Sci USA 1988; 85: 2135-9.
17. 17. Hickey MJ, Williams SA, Roth GJ. Human platelet glycoprotein IX: an adhesive prototype of leucine-rich glycoproteins with flank-center-flank structures. Proc Natl Acad Sci USA 1989; 86: 6773-7.
18. 18. Shimomura T, Fujimara K, Maehama S et al. Rapid purification and characterisation of human platelet glycoprotein V: the amino acid sequence contains leucine-rich repetitive modules as in glycoprotein Ib. Blood 1990; 75: 2349-56.
19. 19. Ware J. Molecular analysis of the platelet glycoprotein Ib/V/IX receptor. Thromb Haemost 1998; 79: 466-78.
20. 20. Caen JP, Nurden AT, George JN. Glanzmann's thrombasthenia: The spectrum of clinical disease. Blood 1990; 75: 1383-95.
21. 21. Phillips DR, Charo IF, Parise LV, Fitzgerald LA. The platelet membrane glycoprotein IIb-IIIa complex. Blood 1988; 71: 831-43.
22. 22. Kloczewiak M, Timmons S, Lukas TJ, Hawiger J. Platelet receptor recognition site on human fibrinogen. Synthesis and structure-function relationship of peptides corresponding to the carboxy-terminal segment of the γ chain. Biochemistry 1984; 23: 1767-74.
23. 23. D'Souza SE, Ginsberg MH, Matsueda GR, Plow EF. A discrete sequence in platelet integrin is involved in ligand recognition. Nature 1991; 350: 66-8.
24. 24. Plow EF, D'Souza SE, Ginsberg MH. Ligand binding to GP IIb-IIIa: a status report. Semin Thromb Hemost 1992; 18: 324-32.
25. 25. Shattil SJ, Kashiwagi H, Pampori N. Integrin signalling: the platelet paradigm. Blood 1998; 91: 2645-57.
26. 26. Kroll MH, Schafer AI. Biochemical mechanisms of platelet activation. Blood 1989; 74: 1181-95.
27. 27. Antiplatelet Trialists' Collaboration. Secondary prevention of vascular disease by prolonged antiplatelet treatment. Br Med J 1998; 296: 320-31.
28. 28. Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy. I: prevention of death, myocardial infarction and stroke by prolonged antiplatelet therapy in various categories of patients. Br Med J 1994; 308: 81-106.
29. 29. Sharis PJ, Cannon CP, Loscalzo J. The antiplatelet effects of ticlopidine and clopidogrel. Ann Intern Med 1998; 129: 394-405.
30. 30. CAPRIE steering committee. A randomised, blinded trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996; 348: 1329-39.
31. 31. Coukell AJ, Markham A. Clopidogrel. Drugs 1997; 54: 745-50.
32. 32. Schror K. Antiplatelet drugs. A comparative review. Drugs 1995; 50: 7-28.
33. 33. Patrono C. Aspirin as an antiplatelet drug. N Engl J Med 1994; 330: 1287-94.
34. 34. Willard JE, Lange RA, Hillis LD. The use of aspirin in ischaemic heart disease. N Engl J Med 1992; 327: 175-81.
35. 35. Coller BS, Peerschke EI, Scudder LE, Sullivan CA. A murine monoclonal antibody that completely blocks the binding of fibrinogen to platelets produces a thrombasthenic-like state in normal platelets and binds to glycoproteins IIb and/or IIIa. J Clin Invest 1983; 72: 325-38.
36. 36. Tcheng JE, Ellis SG, George BS et al. Pharmaco-dynamics of chimeric glycoprotein IIb/IIIa integrin antiplatelet antibody Fab 7E3 in high-risk coronary angioplasty. Circulation 1994; 90: 1757-64.
37. 37. Topol EJ, Plow EF. Clinical trials of platelet receptor inhibitors. Thromb Haemost 1993; 70: 94-8.
38. 38. The EPIC Investigators. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high risk coronary angioplasty. N Engl J Med 1994; 330: 956-61.
39. 39. Konstantopoulos K, Kamat SG, Schafer AI et al. Shear-induced platelet aggregation is inhibited by in vivo infusion of an anti-glycoprotein IIb/IIIa antibody fragment, c7E3 Fab, in patients undergoing coronary angioplasty. Circulation 1995; 91: 1427-31.
40. 40. Topol EJ, Califf RM, Weismann HF et al., on behalf of the EPIC investigators. Randomised trial of coronary intervention with antibody against platelet IIb/IIIa integrin for reduction of clinical restenosis: results at six months. Lancet 1994; 343: 881-6.
41. 41. The EPILOG investigators. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. N Engl J Med 1997; 336: 1689-96.
42. 42. Plow EF, Marguerie G, Ginsberg M. Fibrinogen, fibrinogen receptors and the peptides that inhibit these interactions. Biochem Pharmacol 1987; 36: 4035-40.
43. 43. Barker PL, Bullens S, Bunting S et al. Cyclic RGD peptide analogues as antiplatelet antithrombotics. J Med Chem 1992; 35: 2040-8.
44. 44. Pierschbacher MD, Ruoslahti E. Cell attachment activity of fibronectin can be duplicated by small synthetic fragments of the molecule. Nature 1984; 309: 30-3.
45. 45. D'Souza SE, Ginsberg MH, Plow EF. Arginyl-glycylaspartic acid (RGD): a cell adhesion motif. Trends Biochem Sci 1991; 16: 246-50.
46. 46. Lefkovits J, Plow EF, Topol EJ. Mechanisms of Disease: Platelet Glycoprotein IIb/IIIa receptors in cardiovascular medicine. N Engl J Med 1995; 332: 1553-9.
47. 47. The IMPACT-II investigators. Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT-II. Lancet 1997; 349: 1422-8.
48. 48. The RESTORE investigators. Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty. Circulation 1997; 96: 1445-53.
49. 49. The platelet receptor inhibition in ischaemic syndrome management (PRISM) study investigators. A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina. N Engl J Med 1998; 338: 1498-505.
50. 50. The platelet receptor inhibition in ischaemic syndrome management in patients limited by unstable signs and symptoms (PRISM-PLUS) study investigators. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non Q-wave myocardial infarction. N Engl J Med 1998; 338: 1488-97.
51. 51. Coller BS. Glycoprotein IIb/IIIa antagonists: Pathophysiologic and therapeutic insights from studies of c7E3 Fab. Thromb Haemost 1997; 78: 730-5.
52. 52. Van Belle E, Lablanche JM, Beuters C. Renaud N, McFadden EP, Bertrand ME. Coronary angioscopic findings in the infarct-related vessel within 1 month of acute myocardial infarction: natural history and the effect of thrombolysis. Circulation 1998; 97: 26-33.
53. 53. Meyer BJ, Badimon JJ, Chesebro JH, Fallen JT, Fuster V, Badimon L. Dissolution of mural thrombosis by specific thrombin inhibition with r-hirudin: Comparison with heparin and aspirin. Circulation 1998; 97: 681-5.
54. 54. Kyrle PA, Chesebro JH, Hayes RM, Rubsamen K, Fuster V, Badimon JJ. Antithrombotic effect of PEG-hirudin compared to heparin and heparin plus c7E3. Circulation 1997; (Suppl. I) 96: 1-41. (Abstr.).
55. 55. Kereiakes DJ, Kleinman NS, Ferguson JJ et al. Pharmacodynamic efficacy, clinical safety and outcomes after prolonged platelet glycoprotein IIb/IIIa receptor blockade with oral Xemilofiban. Results of a multicenter, placebo-controlled, randomized trial. Circulation 1998; 98: 1268-78.
56. 56. Vorchheimer DA, Fuster V. Oral platelet glycoprotein IIb/IIIa receptor antagonists: the present challenge is safety. Circulation 1998; 97: 312-14.
57. 57. SCRIP 1999; No. 2420, 24-5.
58. 58. Kuwahara M, Sugimoto M, Tsuji S et al. Comparative studies on the antiplatelet effects of a humanized antiplatelet glycoprotein IIb/IIIa antibody (YM337) and ReoPro under flow conditions. Thromb Haemost 1998; 80: 28-31.
59. 59. Nichols TC, Bellinger DA, Johnson TA, Lamb MA, Griggs TR. Von Willebrand's disease prevents occlusive thrombosis in stenosed and injured porcine coronary arteries. Circ Res 1986; 59: 15-26.
60. 60. Nichols TC, Bellinger DA, Tate DA, Reddick RL, Read MS, Kock GG, Brinkhous KM, Griggs TR. Von Willebrand factor and occlusive arterial thrombosis. A study in normal and von Willebrand's disease pigs with diet-induced hypercholesterolemia and artherosclerosis. Arteriosclerosis 1990; 10: 449-61.
61. 61. Kroll MH, Hellums DJ, McIntire LV, Schafer AI, Moake LJ. Platelets and shear stress. Blood 1996; 88: 1525-41.